XOMA Corporation

NasdaqGM XOMA

XOMA Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2024: USD -30.12 M

XOMA Corporation Free Cash Flow is USD -30.12 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -15.30% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

XOMA Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -26.12 M, a -266.88% change year over year.
XOMA Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 15.65 M, a 230.59% change year over year.
XOMA Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -11.99 M, a -258.61% change year over year.
XOMA Corporation Free Cash Flow for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 7.56 M, a 141.62% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NasdaqGM: XOMA

XOMA Corporation

CEO	Mr. Owen P. Hughes Jr.
IPO Date	June 6, 1986
Location	United States
Headquarters	2200 Powell Street
Employees	13
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

XOMA Corporation operates as a biotechnology royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with approximately 70 assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Key trends

Past 5 years